Amgenvs.Neurocrine Biosciences
AMGN vs NBIX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 11× larger than Neurocrine Biosciences by market cap; year to date, Neurocrine Biosciences leads (+24.9% vs +11.0%).
Side by side
| AMGN | NBIX | |
|---|---|---|
| Market cap | $196B | $17.7B |
| Price | $363.39 | $177.11 |
| Today | −0.1% | −1.9% |
| Return YTD | +11.0% | +24.9% |
| Return 1Y | +21.0% | +31.3% |
| P/E | 25.1 | 26.4 |
| P/S | 5.3 | 5.7 |
| P/B | 21.3 | 5.2 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
AmgenAMGN
Veteran American biotech with a broad portfolio in oncology, immunology and bone diseases — and an obesity candidate (MariTide) in the pipeline.
Full AMGN profile →Neurocrine BiosciencesNBIX
Biopharma focused on neurological and endocrine diseases (Ingrezza).
Full NBIX profile →More comparisons in Biotech & innovation
See where AMGN and NBIX sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →